Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa Sells 10,000 Shares

Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.62, for a total transaction of $16,200.00. Following the completion of the transaction, the chief executive officer now owns 66,712 shares in the company, valued at $108,073.44. The trade was a 13.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Calidi Biotherapeutics Stock Performance

CLDI traded down $0.29 on Wednesday, reaching $1.44. The company’s stock had a trading volume of 720,608 shares, compared to its average volume of 507,528. Calidi Biotherapeutics, Inc. has a 1 year low of $0.73 and a 1 year high of $19.70. The firm has a 50 day moving average of $1.68.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.20. As a group, equities research analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Institutional Trading of Calidi Biotherapeutics

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. Delta Investment Management LLC lifted its holdings in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 1,955.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 210,230 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. Delta Investment Management LLC owned 0.41% of Calidi Biotherapeutics worth $42,000 as of its most recent filing with the SEC. 12.53% of the stock is currently owned by institutional investors and hedge funds.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.